prescribe semaglutide SkinnyRx Compound Semaglutide

While research has primarily focused on men, women theoretically benefit from its fat-loss and recovery effects as well

The latest quick win is the suite of GLP-1 medications that include Semaglutide, and similar medications for rapid and significant weight loss

Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade

In pancreatic beta cells, the combination of GIP and GLP-1 receptor activation produces synergistic insulin secretion

Patients undergoing bariatric surgery can expect to lose a significant amount of excess body weight, often 60% to 70% or even more [11]